Julie Ho1, Chris Wiebe, Ian W Gibson, Sabine Hombach-Klonisch, Ang Gao, Claudio Rigatto, Martin Karpinski, Leroy Storsley, Peter W Nickerson, David N Rush. 1. 1 Section of Nephrology, University of Manitoba, Winnipeg, Manitoba, Canada. 2 Manitoba Centre for Proteomics and Systems Biology, University of Manitoba, Winnipeg, Manitoba, Canada. 3 Department of Pathology, University of Manitoba, Winnipeg, Manitoba, Canada. 4 Department of Anatomy and Cell Science, University of Manitoba, Winnipeg, Manitoba, Canada. 5 Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada. 6 Address correspondence to: Julie Ho, M.D., F.R.C.P.C., Sections of Nephrology and Biomedical Proteomics, Health Sciences Centre, GE421C, 820 Sherbrook Street, Winnipeg, MB R3A 1R9.
Abstract
BACKGROUND: We have demonstrated that 6-month urinary CCL2: Cr is a predictor of interstitial fibrosis and tubular atrophy (IFTA) on 24-month biopsy and death-censored graft loss. However, IFTA is no longer considered prognostically significant, whereas patients with graft loss frequently have interstitial fibrosis and inflammation (IF+i=ci>0+i>0). As early CCL2: Cr predicts late graft loss, the goal of this study was to determine if 6-month urinary CCL2: Cr was a predictor of IF+i at 24 months. METHODS: Urinary CCL2 at 6 months was measured with ELISA and correlated with IF+i on 24-month surveillance biopsies from a prospective, multicenter adult renal transplant cohort (n=111). RESULTS: Six-month urinary CCL2: Cr was significantly higher in IF+i and transplant glomerulopathy patients compared with normal histology at 24 months. By multivariate analysis, 6-month urinary CCL2: Cr was independently correlated with IF+i at 24 months (OR 2.78, 95% CI 1.38-6.12, AUC 0.695, P=0.003). Six-month urinary CCL2: Cr was also an independent correlate of 6-month IF+i (OR 1.99, 95% CI 1.03-4.18, AUC 0.63, P=0.04). Six-month urinary CCL2: Cr distinguished noninflamed renal tissue (normal, fibrosis) from IF+i with a sensitivity/specificity of 0.71/0.62 at a cutoff of 15 ng CCL2/mmol Cr (AUC 0.695, P=0.003, n=91). CONCLUSIONS: Urinary CCL2: Cr may be useful for the noninvasive identification of patients with or at risk for IF+i. These patients may benefit from avoidance of drug minimization/withdrawal protocols and more intensive post-transplant surveillance. Furthermore, urinary CCL2: Cr may also identify individuals who may benefit from novel interventional trials targeting IF+i.
BACKGROUND: We have demonstrated that 6-month urinary CCL2: Cr is a predictor of interstitial fibrosis and tubular atrophy (IFTA) on 24-month biopsy and death-censored graft loss. However, IFTA is no longer considered prognostically significant, whereas patients with graft loss frequently have interstitial fibrosis and inflammation (IF+i=ci>0+i>0). As early CCL2: Cr predicts late graft loss, the goal of this study was to determine if 6-month urinary CCL2: Cr was a predictor of IF+i at 24 months. METHODS: Urinary CCL2 at 6 months was measured with ELISA and correlated with IF+i on 24-month surveillance biopsies from a prospective, multicenter adult renal transplant cohort (n=111). RESULTS: Six-month urinary CCL2: Cr was significantly higher in IF+i and transplant glomerulopathypatients compared with normal histology at 24 months. By multivariate analysis, 6-month urinary CCL2: Cr was independently correlated with IF+i at 24 months (OR 2.78, 95% CI 1.38-6.12, AUC 0.695, P=0.003). Six-month urinary CCL2: Cr was also an independent correlate of 6-month IF+i (OR 1.99, 95% CI 1.03-4.18, AUC 0.63, P=0.04). Six-month urinary CCL2: Cr distinguished noninflamed renal tissue (normal, fibrosis) from IF+i with a sensitivity/specificity of 0.71/0.62 at a cutoff of 15 ng CCL2/mmol Cr (AUC 0.695, P=0.003, n=91). CONCLUSIONS: Urinary CCL2: Cr may be useful for the noninvasive identification of patients with or at risk for IF+i. These patients may benefit from avoidance of drug minimization/withdrawal protocols and more intensive post-transplant surveillance. Furthermore, urinary CCL2: Cr may also identify individuals who may benefit from novel interventional trials targeting IF+i.
Authors: Joachim H Ix; Ronit Katz; Nisha Bansal; Meredith Foster; Daniel E Weiner; Russell Tracy; Vasantha Jotwani; Jan Hughes-Austin; Dianne McKay; Francis Gabbai; Chi-Yuan Hsu; Andrew Bostom; Andrew S Levey; Michael G Shlipak Journal: Am J Kidney Dis Date: 2016-12-23 Impact factor: 8.860
Authors: S G Mansour; J Puthumana; P P Reese; I E Hall; M D Doshi; F L Weng; B Schröppel; H Thiessen-Philbrook; M Bimali; C R Parikh Journal: Kidney Int Rep Date: 2017-03-31
Authors: Julie Ho; Atul Sharma; Kristine Kroeker; Robert Carroll; Sacha De Serres; Ian W Gibson; Patricia Hirt-Minkowski; Anthony Jevnikar; S Joseph Kim; Greg Knoll; David N Rush; Chris Wiebe; Peter Nickerson Journal: BMJ Open Date: 2019-04-11 Impact factor: 2.692
Authors: Elizabeth Grunz-Borgmann; Valeri Mossine; Kevin Fritsche; Alan R Parrish Journal: BMC Complement Altern Med Date: 2015-12-15 Impact factor: 3.659
Authors: Jared J Grantham; Arlene B Chapman; Jaime Blais; Frank S Czerwiec; Olivier Devuyst; Ron T Gansevoort; Eiji Higashihara; Holly Krasa; Wen Zhou; John Ouyang; Ronald D Perrone; Vicente E Torres Journal: Nephrol Dial Transplant Date: 2017-06-01 Impact factor: 5.992